Up Approx. 15%, Low Float (Nasdaq: APRE) Surges On Promising Early-Stage Clinical Data

Aprea Therapeutics, Inc. (Nasdaq: APRE) is up approximately 15% and it could just be the start.

*Sponsored Up Approx. 15%, Low Float (Nasdaq: APRE) Surges On Promising Early-Stage Clinical Data June 25th Greetings Readers, Aprea Therapeutics, Inc. (Nasdaq: APRE) is up approximately 15% and it could just be the start. On the heels of breaking news today, APRE is in surge mode as the company's announcement continues to spread. Check it out: Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center From the article: “We are excited by the preclinical data generated by independent researchers, and the early clinical signal of APR-1051 in an HPV-positive cancer patient,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea Therapeutics. “We believe that APR-1051 could offer significant differentiation in the competitive oncology landscape, as a single agent, as well as in combination with checkpoint inhibitors.” With strong news and a low float under 4Mn shares, APRE could be on the verge of earning serious buzz today. Read my initial (Nasdaq: APRE) report below and consider this company for your watchlist. ----- A biopharma company at the forefront of oncology innovation is quickly gaining attention for its promising clinical pipeline. With several experimental therapies advancing through trials, this team is targeting some of the most challenging cancer types—those with limited current treatment options. Early results are fueling optimism about the potential for meaningful impact on patient outcomes, especially for individuals with hard-to-treat disease. As the field of targeted cancer therapies continues to expand, it’s becoming clear that this under-the-radar company is one to watch closely. Its rigorous approach to clinical development and focus on patient-centric solutions set it apart in a crowded market. Now is the time to take note: this emerging biopharma company is poised to make waves, and its progress could soon reshape standards of care. And with a noticeably low float, several analysts providing price targets with significant upside potential, and a strong flow of news sharing positive developments throughout the 1st half of 2025, this Nasdaq biopharma profile has shot up up my watchlist. Take a moment right now to look closer at: *Aprea Therapeutics, Inc. (Nasdaq: APRE)* Aprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors but to minimize the effect on normal, healthy cells, decreasing the risk of toxicity that is frequently associated with chemotherapy and other treatments. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, colorectal, prostate, and breast cancers. And based on several potential catalysts, (Nasdaq: APRE) could become a serious breakout target. Take a look: No. 1 - Could A Low Float Create A Volatile Environment On A Daily Basis? No. 2 - Multiple Analyst Targets Suggest Triple-Digit Upside Potential For APRE. No. 3 - A Key Trial Proceeds Forward With 1st Patient Dosing (Open Label Data Expected 2nd Half Of 2025). No. 4 - Aprea Enters Into Agreement With MD Anderson Cancer Center To Support Preclinical Research. No. 5 - Aprea's Shares Update On Strategic Evolution Of Its Patent Portfolio. But more on those in a second... Aprea Therapeutics (Nasdaq: APRE) - Key Company Details Precision Oncology Via Novel Synthetic Lethality Therapeutics All programs are designed to address significant unmet medical need, are potentially synergistic with other anticancer therapies, and potentially differentiated in safety and tolerability. ATR – Ataxia telangiectasia and Rad3‐related, DDR – DNA Damage Response, BID – Twice Daily WEE1 Program: APR-1051 WEE1 is a protein kinase that helps regulate the cell cycle by preventing abnormal progression. Specifically, WEE1 prevents the premature entry of cells into both the DNA synthetic (S phase) and cell division (mitosis) phases of the cell cycle, ensuring that cells only divide after properly duplicating and repairing their DNA. By performing these functions, WEE1 plays a crucial role in maintaining genome stability and cell survival, especially during periods of rapid cell division, a hallmark of cancer. As a result, cancer cells are particularly reliant on WEE1 for growth and survival. APR-1051 is an orally bioavailable, highly potent, and selective small molecule inhibitor of WEE1. APR-1051 has demonstrated strong anti-proliferative activity across multiple cancer cell lines and in mouse models. One cancer-associated alteration that enhances sensitivity to APR-1051, in both cell culture and mouse models, is the overexpression of Cyclin E, a gene that promotes cell cycle progression. This makes APR-1051 particularly promising for cancers that overexpress Cyclin E, such as therapy-resistant breast and ovarian cancers. In addition, APR-1051 exhibits favorable pharmacodynamic properties, including lower off-target inhibition of three members of the PLK family of kinases (PLK1, PLK2, and PLK3). This selective inhibition profile may contribute to improved therapeutic value and reduced toxicity. ATR Program: ATRN-119 The ataxia telangiectasia and Rad3-related (ATR) kinase is a key regulator of the DNA damage response, playing a central role in maintaining genomic instability and controlling cell proliferation. By coordinating cellular responses to replication stress and damage, ATR allows cancer cells to survive despite rapid proliferation and defective DNA repair mechanisms. Inhibiting ATR disrupts these survival pathways, potentially making cancer cells more vulnerable to treatment. To leverage this vulnerability, Aprea Therapeutics has developed a highly potent and selective ATR inhibitor, ATRN-119, the first macrocyclic ATR inhibitor to enter clinical trials, representing a novel class of targeted therapy. With the potential to enhance outcomes for patients worldwide, ATRN-119 exemplifies the company's commitment to precision medicine and innovation in oncology. Robust DDR Development Pipeline Milestones 2024-2026 Accomplished And Anticipated Clinical Milestones Grab Sources: APRE Website. APRE Presentation. ----- And based on the 5 potential breakout catalysts I listed above, (Nasdaq: APRE) has earned my immediate focus. Check them out: No. 1 APRE Potential Catalyst - Could A Low Float Create A Volatile Environment On A Daily Basis? According to info from the Yahoo Finance website, APRE has a very low float. The website reports this profile to have roughly 3.48Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If positive company news appears in the midway part of 2025, could it provide a breakout spark? ----- No. 2 APRE Potential Catalyst - Multiple Analyst Targets Suggest Triple-Digit Upside Potential For APRE. TipRanks is currently reporting at least 3 must-see analyst targets highlighting the serious upside potential APRE could contain. Take a look: From Tuesday's close, all 3 of these targets are suggesting at least 500% potential upside. Could (Nasdaq: APRE) be severely undervalued from current chart levels? ----- No. 3 APRE Potential Catalyst - A Key Trial Proceeds Forward With 1st Patient Dosing (Open Label Data Expected 2nd Half Of 2025). Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI Inhibition DOYLESTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that a patient with HPV+ head and neck squamous cell carcinoma (HNSCC) has been dosed in the ongoing ACESOT-1051 clinical trial evaluating APR-1051. This is the first patient to be dosed in Cohort 5 (70 mg once daily) of the study. Open label data from the study are expected in the second half of 2025. ... “Enrollment of the first patient with HPV+ head and neck cancer in the Phase 1 ACESOT-1051 trial is an important step and is in line with our goal of identifying patient populations most likely to benefit from WEE1 inhibition,” said Philippe Pultar MD., Senior Medical Advisor and Lead WEE1 Clinical Development of Aprea. “We are pleased with the progress of the trial and encouraged by the safety profile of APR-1051 to date. We look forward to continuing the study as we work toward identifying the optimal dose for future studies. We continue to believe that APR-1051 has best in class potential.” ... Read the full article here. ----- No. 4 APRE Potential Catalyst - Aprea Enters Into Agreement With MD Anderson Cancer Center To Support Preclinical Research. Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, announced today that it has entered into a Material Transfer Agreement (MTA) with MD Anderson Cancer Center. Under the agreement, Aprea will supply its proprietary WEE1 kinase inhibitor, APR-1051, to support preclinical research aimed at exploring its potential in treating HPV+ and HPV- head and neck squamous cell carcinoma (HNSCC) expressing genomic markers of replication stress. The agreement will enable the research group at MD Anderson to conduct a series of pre-clinical experiments designed to generate preliminary efficacy and mechanistic data to support future clinical trials and treatment regimens. The goal of this research is to further characterize the therapeutic potential of APR-1051 in HNSCC and generate insights that could support future clinical development strategies. The studies will include combining APR-1051 with immune checkpoint inhibitors (ICIs) to treat both HPV+ and HPV- HNSCC tumors harboring genomic markers of replication stress. The project is being overseen by Professors Jeffrey N. Myers, M.D., Ph.D., F.A.C.S., and Abdullah A. Osman, Ph.D., both from the Department of Head and Neck Surgery, MD Anderson Cancer Center. Prof. Myers is the leading expert on head and neck cancers. “This agreement with MD Anderson Cancer Center underscores our commitment to leveraging strong academic partnerships to advance our pipeline of DDR inhibitors,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “HNSCC represents a major global health burden, and prior work conducted at MD Anderson, and published by Professors Myers, Osman and their colleagues, suggests that WEE1 kinase may present a promising therapeutic target. We look forward to the insights that will emerge from this important research.” ... Read the full article here. ----- No. 5 APRE Potential Catalyst - Aprea's Shares Update On Strategic Evolution Of Its Patent Portfolio. Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today provided an update on its existing patent portfolio. “Our strong patent portfolio reflects our commitment to innovation and leadership in the field of DNA Damage Response therapeutics,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “Intellectual property is an essential component of Aprea’s strategy, enabling us to advance first in class and best in class oncology treatments while protecting the value of our assets. Our commitment to securing global intellectual property rights underscores our long-term vision to develop and commercialize breakthrough therapies for difficult to treat cancers.” ... Read the full article here. ----- (Nasdaq: APRE) Recap - 5 Potential Catalysts Lead The Way No. 1 - Could A Low Float Create A Volatile Environment On A Daily Basis? No. 2 - Multiple Analyst Targets Suggest Triple-Digit Upside Potential For APRE. No. 3 - A Key Trial Proceeds Forward With 1st Patient Dosing (Open Label Data Expected 2nd Half Of 2025). No. 4 - Aprea Enters Into Agreement With MD Anderson Cancer Center To Support Preclinical Research. No. 5 - Aprea's Shares Update On Strategic Evolution Of Its Patent Portfolio. ----- Coverage is officially initiated on Aprea Therapeutics, Inc. (Nasdaq: APRE). I'll be in touch with updates soon. Be on the lookout. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 06/25/2025 and ending on 06/25/2025 to publicly disseminate information about (APRE:US) via digital communications. Under this agreement, SWN Media LLC has been paid twenty two thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (APRE:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/apre-fszxx/#details

SWN Media | 160 W. Camino Real Unit 886 | Boca Raton, FL 33432 US Unsubscribe | Update Profile | Constant Contact Data Notice